Ivan Bunganič

Budesonide 9 mg Is at Least as Effective as Mesalamine 4.5 g in Patients With Mildly to Moderately Active Crohn's Disease

A Tromm, Ivan Bunganič, Eva Tomsová et al. · Gastroenterology · 2010 · 90 citations · Full text

Inflammation, Anti-inflammatory, Gastrointestinal Pharmacology +6

Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study

Marc Ferrante, Geert D’Haens, Vipul Jairath et al. · The Lancet · 2024 · 76 citations

Moderately-to-severely Active Crohn, Immunology, Gastroenterology +5

3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: A double-blind, double-dummy, randomised trial

Ivan Bunganič, E. А. Belousova, Limas Kupčinskas et al. · Journal of Crohn s and Colitis · 2010 · 61 citations · Full text

ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension

Séverine Vermeire, Bruce E. Sands, Herbert Tilg et al. · ˜The œLancet. Gastroenterology & hepatology · 2022 · 58 citations

Inflammation, Gastrointestinal Pharmacology, Phase 2B +6

Long‐term safety and efficacy of acotiamide in functional dyspepsia (postprandial distress syndrome)—results from the European phase 3 open‐label safety trial

Jan Tack, Juris Pokrotnieks, Gediminas Urbonas et al. · Neurogastroenterology & Motility · 2018 · 51 citations · Full text

Pain Disorders, Pain Medicine, Pharmacotherapy +21